v3.26.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Manufacturing Commitments and Contingencies

The following table summarizes manufacturing commitments and contingencies as of the period indicated (in thousands):

 

 

 

March 31, 2026

 

GEMA:

 

 

 

Achievement of certain milestones related to validation of API supplied by GEMA and
    regulatory approval of MOLBREEVI drug substance produced at GEMA

 

$

200

 

PARI:

 

 

 

Achievement of various development activities and regulatory approval of proprietary
     nebulizer utilized to administer MOLBREEVI

 

 

573

 

Total manufacturing and other commitments and contingencies

 

$

773